TTY Biopharm Company Limited would receive milestone payment from German pharmaceutical company for co-development of liposome product-Pegylipo in Europe. The Company has co-developed with German pharmaceutical company for liposome product-Pegylipo in European markets. Fourth patient has been recruited for clinical trial and the Company will receive milestone payment of EUR 540,000 based on agreement.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
76.6 TWD | +0.13% | +0.79% | -4.73% |
Mar. 14 | TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 08 | TTY Biopharm Company Limited Announces Change of CFO and Financial Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.73% | 584M | |
+25.83% | 661B | |
+26.60% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.58% | 231B | |
+5.38% | 200B | |
-8.92% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4105 Stock
- News TTY Biopharm Company Limited
- TTY Biopharm Company Limited Receives Milestone Payment from German Pharmaceutical Company for Co-Development of Liposome Product-Pegylipo in Europe